2023年5月2日

精密生物科學2023年第一季度業績報告5月9日,2023杜倫,北卡羅來納州——(業務線)精密生物科學有限公司(納斯達克:DTIL),臨床階段基因編輯公司發展ARCUS®的車體外同種異體T和體內基因編輯療法,今天宣布將發布2023年第一季度業績,並提供一個業務更新5月9日,2023年。精密生物科學公司是一個臨床階段生物科技公司,致力於改善生活(DTIL)的小說和專有ARCUS®基因組編輯平台。ARCUS是一個非常具體的和通用的基因組編輯平台,設計與治療安全、交付和控製。使用ARCUS,公司的管道由多個“現成的”汽車T免疫療法臨床候選人和幾個編輯體內基因治療候選人用來治療基因和沒有足夠的治療存在的傳染病。關於精密生物科學的更多信息請訪問www.precisionbiosciences.com。聯係PharmiWeb.com是歐洲領先業界讚助的製藥行業門戶,提供最新的工作,新聞、特寫和事件列表。在PharmiWeb.com上提供的信息的目的是支持,而不是替代關係,之間存在一個病人/網站訪問者和他/她的醫生。這個網站是受多重保護和穀歌的隱私政策和服務條款適用。跟著我們版本:2022.9.21.3你離開PharmiWeb.com免責聲明:你現在離開PharmiWeb.com網站,要一個網站,不是由我們操作。 We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com. PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly. Continue